Amphastar Pharmaceuticals annual operating margin
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Amphastar Pharmaceuticals's operating margin was 19.50% for fiscal 2025.
View full Amphastar Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 19.50% | −8.56 pp |
| 2024 | 2024-12-31 | 28.06% | −2.51 pp |
| 2023 | 2023-12-31 | 30.57% | +9.03 pp |
| 2022 | 2022-12-31 | 21.54% | +5.58 pp |
| 2021 | 2021-12-31 | 15.96% | +12.83 pp |
| 2020 | 2020-12-31 | 3.13% | +3.14 pp |
| 2019 | 2019-12-31 | −0.01% | +2.91 pp |
| 2018 | 2018-12-31 | −2.93% | −2.40 pp |
| 2017 | 2017-12-31 | −0.53% | −6.55 pp |
| 2016 | 2016-12-31 | 6.03% | +8.77 pp |
| 2015 | 2015-12-31 | −2.74% | +5.80 pp |
| 2014 | 2014-12-31 | −8.54% | −16.16 pp |
| 2013 | 2013-12-31 | 7.61% | −4.81 pp |
| 2012 | 2012-12-31 | 12.43% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 21.60% | −2.58 pp |
| Q1 2026 | 2026-03-31 | 7.96% | −13.91 pp |
| Q4 2025 | 2025-12-31 | 19.45% | −4.76 pp |
| Q3 2025 | 2025-09-30 | 13.20% | −16.64 pp |
| Q2 2025 | 2025-06-30 | 24.19% | −6.09 pp |
| Q1 2025 | 2025-03-31 | 21.87% | −6.07 pp |
| Q4 2024 | 2024-12-31 | 24.20% | −6.11 pp |
| Q3 2024 | 2024-09-30 | 29.83% | −10.42 pp |
| Q2 2024 | 2024-06-30 | 30.27% | +4.95 pp |
| Q1 2024 | 2024-03-31 | 27.94% | +4.06 pp |
| Q4 2023 | 2023-12-31 | 30.31% | +2.29 pp |
| Q3 2023 | 2023-09-30 | 40.25% | +20.92 pp |
| Q2 2023 | 2023-06-30 | 25.32% | +5.22 pp |
| Q1 2023 | 2023-03-31 | 23.88% | +5.92 pp |
| Q4 2022 | 2022-12-31 | 28.02% | +7.96 pp |
| Q3 2022 | 2022-09-30 | 19.34% | −2.74 pp |
| Q2 2022 | 2022-06-30 | 20.10% | +9.72 pp |
| Q1 2022 | 2022-03-31 | 17.96% | +7.95 pp |
| Q4 2021 | 2021-12-31 | 20.06% | +17.06 pp |
| Q3 2021 | 2021-09-30 | 22.08% | +17.86 pp |
| Q2 2021 | 2021-06-30 | 10.39% | +13.79 pp |
| Q1 2021 | 2021-03-31 | 10.00% | +1.17 pp |
| Q4 2020 | 2020-12-31 | 3.00% | +3.29 pp |
| Q3 2020 | 2020-09-30 | 4.22% | +1.22 pp |
| Q2 2020 | 2020-06-30 | −3.41% | −4.64 pp |
| Q1 2020 | 2020-03-31 | 8.83% | +12.81 pp |
| Q4 2019 | 2019-12-31 | −0.29% | −2.02 pp |
| Q3 2019 | 2019-09-30 | 3.00% | −0.38 pp |
| Q2 2019 | 2019-06-30 | 1.23% | +5.37 pp |
| Q1 2019 | 2019-03-31 | −3.98% | +12.77 pp |
| Q4 2018 | 2018-12-31 | 1.72% | +4.89 pp |
| Q3 2018 | 2018-09-30 | 3.38% | +8.46 pp |
| Q2 2018 | 2018-06-30 | −4.14% | −7.49 pp |
| Q1 2018 | 2018-03-31 | −16.74% | −19.22 pp |
| Q4 2017 | 2017-12-31 | −3.17% | +4.42 pp |
| Q3 2017 | 2017-09-30 | −5.08% | −14.11 pp |
| Q2 2017 | 2017-06-30 | 3.35% | −11.83 pp |
| Q1 2017 | 2017-03-31 | 2.48% | −4.39 pp |
| Q4 2016 | 2016-12-31 | −7.59% | −26.28 pp |
| Q3 2016 | 2016-09-30 | 9.03% | +14.89 pp |
| Q2 2016 | 2016-06-30 | 15.18% | +34.24 pp |
| Q1 2016 | 2016-03-31 | 6.86% | +19.63 pp |
| Q4 2015 | 2015-12-31 | 18.68% | +31.26 pp |
| Q3 2015 | 2015-09-30 | −5.87% | +7.22 pp |
| Q2 2015 | 2015-06-30 | −19.05% | −16.66 pp |
| Q1 2015 | 2015-03-31 | −12.76% | −8.47 pp |
| Q4 2014 | 2014-12-31 | −12.57% | −12.95 pp |
| Q3 2014 | 2014-09-30 | −13.09% | −32.26 pp |
| Q2 2014 | 2014-06-30 | −2.39% | — |
| Q1 2014 | 2014-03-31 | −4.29% | — |
| Q3 2013 | 2013-09-30 | 0.38% | — |
| Q2 2013 | 2013-06-30 | 19.16% | — |
Over the last five reported fiscal years, Amphastar Pharmaceuticals's operating margin increased from 3.13% to 19.50%, a change of +16.37 percentage points. The latest reported quarter, Q2 2026, shows 21.60%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Amphastar Pharmaceuticals filings at SEC.gov ↗